YDES — YD Bio Income Statement
0.000.00%
Last trade - 00:00HealthcareAdventurousMicro Cap
Annual income statement for YD Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 0.364 | 0.35 | 0.51 |
| Cost of Revenue | |||
| Gross Profit | 0.133 | 0.153 | 0.155 |
| Selling / General / Administrative Expenses | |||
| Research And Development | |||
| Unusual Expense / Income | |||
| Total Operating Expenses | 0.465 | 0.36 | 1.97 |
| Operating Profit | -0.101 | -0.01 | -1.46 |
| Total Net Non Operating Interest Income / Expense | |||
| Other Net Non Operating Costs | |||
| Net Income Before Taxes | -0.048 | 0.018 | -1.39 |
| Provision for Income Taxes | |||
| Net Income After Taxes | -0.051 | 0.014 | -1.41 |
| Net Income Before Extraordinary Items | |||
| Net Income | -0.051 | 0.014 | -1.41 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | -0.051 | 0.014 | -1.41 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -0 | 0 | -0.02 |